Brokers Set Expectations for Entasis Therapeutics Holdings Inc.’s Q2 2022 Earnings (NASDAQ:ETTX)

Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX – Get Rating) – Equities research analysts at Wedbush reduced their Q2 2022 earnings estimates for Entasis Therapeutics in a research note issued on Thursday, April 28th. Wedbush analyst R. Driscoll now expects that the company will earn ($0.28) per share for the quarter, down from their previous estimate of ($0.27). Wedbush currently has a “Neutral” rating and a $1.80 price target on the stock. Wedbush also issued estimates for Entasis Therapeutics’ Q3 2022 earnings at ($0.24) EPS and FY2022 earnings at ($1.08) EPS.

Entasis Therapeutics (NASDAQ:ETTX – Get Rating) last released its earnings results on Wednesday, April 27th. The company reported ($0.32) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.09).

Several other equities research analysts have also issued reports on ETTX. Zacks Investment Research lowered Entasis Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, March 10th. Alliance Global Partners lowered Entasis Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, March 16th. Finally, HC Wainwright lowered Entasis Therapeutics from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $6.00 to $1.80 in a report on Friday, March 4th. Four analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, Entasis Therapeutics has a consensus rating of “Hold” and a consensus target price of $3.15.

NASDAQ:ETTX opened at $1.88 on Monday. Entasis Therapeutics has a fifty-two week low of $1.40 and a fifty-two week high of $3.88. The stock’s 50-day moving average is $1.83 and its two-hundred day moving average is $2.14. The stock has a market cap of $89.96 million, a PE ratio of -1.68 and a beta of 1.60.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Geode Capital Management LLC increased its position in Entasis Therapeutics by 10.5% in the 4th quarter. Geode Capital Management LLC now owns 102,927 shares of the company’s stock worth $225,000 after buying an additional 9,759 shares during the period. Renaissance Technologies LLC increased its position in shares of Entasis Therapeutics by 3.5% during the fourth quarter. Renaissance Technologies LLC now owns 323,345 shares of the company’s stock valued at $708,000 after purchasing an additional 10,800 shares during the period. Two Sigma Investments LP increased its position in shares of Entasis Therapeutics by 13.4% during the third quarter. Two Sigma Investments LP now owns 186,230 shares of the company’s stock valued at $622,000 after purchasing an additional 22,001 shares during the period. Dimensional Fund Advisors LP bought a new stake in shares of Entasis Therapeutics during the third quarter valued at approximately $87,000. Finally, Jane Street Group LLC bought a new stake in shares of Entasis Therapeutics during the third quarter valued at approximately $107,000. 9.27% of the stock is currently owned by institutional investors.

Entasis Therapeutics Company Profile (Get Rating)

Entasis Therapeutics Holdings Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii.

Read More